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Abstract 
Background: Overexpression of cyclin D1 dependent kinases 4 and 6 (CDK4/6) is a common feature of many human 
cancers including leukemia. LEE011 is a novel inhibitor of both CDK4 and 6. To date, the molecular function of LEE011 
in leukemia remains unclear.
Methods: Leukemia cell growth and apoptosis following LEE011 treatment was assessed through CCK‑8 and annexin 
V/propidium iodide staining assays. Cell senescence was assessed by β‑galactosidase staining and p16INK4a expression 
analysis. Gene expression profiles of LEE011 treated HL‑60 cells were investigated using an Arraystar Human LncRNA 
array. Gene ontology and KEGG pathway analysis were then used to analyze the differentially expressed genes from 
the cluster analysis.
Results: Our studies demonstrated that LEE011 inhibited proliferation of leukemia cells and could induce apoptosis. 
Hoechst 33,342 staining analysis showed DNA fragmentation and distortion of nuclear structures following LEE011 
treatment. Cell cycle analysis showed LEE011 significantly induced cell cycle G1 arrest in seven of eight acute leukemia 
cells lines, the exception being THP‑1 cells. β‑Galactosidase staining analysis and p16INK4a expression analysis showed 
that LEE011 treatment can induce cell senescence of leukemia cells. LncRNA microarray analysis showed 2083 dif‑
ferentially expressed mRNAs and 3224 differentially expressed lncRNAs in LEE011‑treated HL‑60 cells compared with 
controls. Molecular function analysis showed that LEE011 induced senescence in leukemia cells partially through 
downregulation of the transcriptional expression of MYBL2.
Conclusions: We demonstrate for the first time that LEE011 treatment results in inhibition of cell proliferation and 
induction of G1 arrest and cellular senescence in leukemia cells. LncRNA microarray analysis showed differentially 
expressed mRNAs and lncRNAs in LEE011‑treated HL‑60 cells and we demonstrated that LEE011 induces cellular 
senescence partially through downregulation of the expression of MYBL2. These results may open new lines of inves‑
tigation regarding the molecular mechanism of LEE011 induced cellular senescence.
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Background
Acute leukemia  is the most common pediatric malig-
nancy constituting more than 30% of all childhood 
cancers [1]. Approximately 300 important genes have 
been reported to be altered in hematologic malignan-
cies. Pediatric acute myeloid leukemia (AML) accounts 
for more than 50% of pediatric acute leukemia patient 
deaths. More effective therapeutic strategies are needed 
to improve prognosis. Recently, the potential therapeu-
tic application of CDK4/6 inhibitors in a range of can-
cers has been considered.
The proteins encoded by CDK4 and 6 are members of 
the Ser/Thr protein kinase family [2]. Both CDK4 and 
6 are important for cell cycle regulation, specifically G1 
phase progression, with their activity strictly restricted 
to the G1-S phase [3–5]. Mutations in these genes have 
been found to be significantly associated with tumorigen-
esis of several cancers [6, 7]. It is now believed that the 
vast majority of human tumors exhibit deregulation of 
the CDK4/6-cyclin D-INK4-RB pathway through multi-
ple mechanisms [8–10]. CDK4/6 amplification or over-
expression has also been observed in a range of tumors, 
including lymphomas, melanomas, gliomas, sarcomas, 
carcinomas of the breast and leukemias. For example, 
CDK6 promoter related chromosomal translocation 
leads to CDK6 overexpression, which has been reported 
in B cell lymphocytic leukemias and splenic marginal 
zone lymphoma [11, 12].
Several pharmacological inhibitors of CDK4/6 have 
been developed and many are currently being tested 
in clinical trials. One CDK4/6 selective inhibitor, 
PD-0332991, causes G1 arrest and growth inhibition 
in xenograft models of human tumor cell lines includ-
ing breast, ovary, lung and multiple myeloma. Another 
CDK4/6 inhibitor, LY2835219, has been reported to 
inhibit CDK4 and 6 at very low concentrations, result-
ing in proliferation inhibition and G1 cell cycle arrest 
[13]. GCS-100 is a non-selective CDK6 inhibitor which 
induces inhibition of proliferation and apoptosis in mye-
loma cell lines [14]. KBH-A42 is a new synthetic histone 
deacetylase inhibitor which can effectively inhibit the 
growth of several cancer cells [15]. Results suggest that 
the molecular mechanism of KBH-A42 mediated cell 
cycle arrest may be the result of the down regulation of 
CDK4 and CDK6 [16].
LEE011 is a recently developed CDK4/6 inhibitor [17]. 
LEE011 has shown antiproliferative effects in a panel 
of human cancer cell lines and primary tumor xeno-
grafts. For example, oral administration of LEE011 to 
mice bearing human liposarcoma xenografts resulted 
in approximately 50% reduction in tumors [18]. Further 
studies have shown that treatment with LEE011 sig-
nificantly reduced cell proliferation in 12 of 17 human 
neuroblastoma cell lines [17, 19]. To date, the molecular 
function of LEE011 in leukemia is unclear. In this study 
the antitumor effect of LEE011 was evaluated in leukemia 




Leukemia cell lines HL-60, MV4-11, U937 and K562 
were obtained from the American Type Culture Collec-
tion (ATCC). CCRF, 697 and SHI-1 cell lines (gifts from 
The Cyrus Tang Hematology center of Soochow Uni-
versity). NB4 and THP-1 cell lines (gifts from Hematol-
ogy Institute of Soochow University). All cell lines were 
maintained at 37  °C in the RPMI 1640 (GibcoR, Life 
Technologies, Carlsbad, CA, USA) supplemented with 
10% fetal bovine serum (Invitrogen, Life Technologies, 
Carlsbad, CA, USA). LEE011 (Cat: S7440 Selleck Chemi-
cals, West Paterson, NJ, USA) was dissolved in DMSO 
(Cat: D4540 Sigma-Aldrich, St. Louis, MO, USA).
Patients and samples
Bone marrow specimens were obtained at the time of 
diagnosis from 5 pediatric AML and 5 ALL patients 
between 2014 and 2015. Ethical approval was provided 
by the Children’s Hospital of Soochow University Ethics 
Committee (No. SUEC2013-022), and written informed 
consent was obtained from the parents or guardians. 
They will be given the opportunity to withdraw from 
the research at any time prior to the publication of the 
research findings. The matter of how data will be col-
lected and stored, with reference to the data protection 
legislation will be clarified for participants, with informa-
tion being stored in locked cabinets or on IT hardware 
protected with the highest security software. The main 
clinical and laboratory features of the patient cohort are 
summarized in Tables  1 and 2. Bone marrow mononu-
clear cells (BMNCs) were isolated using Ficoll solution 
within 2 h after bone marrow samples harvested.
Cell proliferation
Cell proliferation analysis was almost same as introduced 
before [20]. Leukemia cells were incubated with DMSO, 
or increasing concentrations of LEE011 (0.05–80  μM) 
for 24  h. CCK8 Kit (Dojindo Molecular Technologies, 
Japan) was used to analyze the cell survival rate. The 
IC50 of LEE011 inhibitor was calculated by Graph Prism 
software.
Cell cycle analysis
Cell cycle analysis was also introduced before [20]. 
Leukemia cells were collected, fixed, incubated with 
1.5  μmol/l propidium iodide (P4170, Sigma-Aldrich, St. 
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Louis, MO, USA) and 25  μg/ml RNase A The samples 
(1 ×  104  cells) and were analyzed with a Beckman Gal-
lios™ Flow Cytometer. Then these data was analyzed with 
cell cycle software (MultiCycle for Windows).
Apoptosis assay
Apoptosis assay was according to the manual operation 
of BD Annexin V Staining Kit (Cat: 556420, BD Bio-
sciences, Franklin Lakes, NJ, USA). All the details have 
been introduced before [20, 21].
Hoechst 33,342 staining analysis
Cells were seeded into 6-well plates, and then treated 
with LEE011 (2 or 5 μM) and cultured at 37 °C for 24 h, 
stained with 0.1 µg/ml Hoechst 33,342 (Sigma, St. Louis, 
MO, USA) for 5 min, then observed with filters for blue 
fluorescence under fluorescence microscopy (OLYMPUS 
IX71; Olympus Corporation, Tokyo, Japan). Abnormal 
nuclear cells were counted between the RO3280 treat-
ment group and DMSO control group [22].
Cell senescence β‑galactosidase staining analysis
Leukemia cells were seeded into 6-well plates, and then 
treated with LEE011 (2 or 5  μM) and cultured at 37  °C 
for 24–72  h, senescence β-galactosidase staining analy-
sis was according to the manufacture of senescence 
β-galactosidase staining kit (Beyotime Corporation, 
C0602, Jiangsu, China). Staining cells were photographed 
with microscopy (OLYMPUS IX71; Olympus Corpora-
tion, Tokyo, Japan). Positive staining cells were counted 
between the LEE011 treatment group and DMSO control 
group.
Analyze the genes and LncRNAs expression profiles related 
with LEE011
HL-60 cells were treated with 1  μM LEE011 and con-
trol group cells were treated with the same volume of 
DMSO 24  h later. Human LncRNA array analysis was 
performed by KangChen Bio-tech, Shanghai P. R. China. 
And experimental details were introduced by Yu et  al. 
[23]. RNA purification and analysis was introduced as 
before [22].
Gene ontology analysis and KEGG pathway analysis the 
genes expression profiles related with LEE011
Gene ontology (GO) analysis introduced before [24] is a 
functional analysis that associates differentially expressed 
mRNAs with GO categories (http://www.geneontology.
org). The lower the P value is, the more significant the 
GO term (a P ≤ 0.05 is recommended). Pathway analysis 
is a functional analysis that maps genes to Kyoto encyclo-
pedia of genes and genomes (KEGG) pathways (http://
www.genome.jp/kegg/) was introduced before [25]. The P 
value (EASE-score, Fisher P value or Hypergeometric P 
value) denotes the significance of the pathway correlated 
to the conditions. The lower the P value is, the more sig-
nificant the correlation (the recommend P value cut-off 
is 0.05).
Western blot analysis
For western blot analysis, protocol is introduced before 
[26]. Blots were blocked and then probed with antibod-
ies against Caspase 3 (Cat: 9661S 1:1000, Cell Signaling 
Technology, Inc. Danvers, MA, USA), Caspase 9 (Cat: 
4501S 1:1000, Cell Signaling Technology, Inc. Danvers, 
Table 1 Pathologic features and inhibition of cell growth by LEE011 in primary culture cells of pediatric ALL
Gender Age Diagnosis ALL typing Chromosome analysis Fusion gene CDK6 IC50 μM
1 F 5 ALL B 46, XX Not detected Positive 2.14
2 M 4 ALL, B 46, XY TEL/AML1(+) Positive 1.73
3 M 3 ALL B ALL/53–54, XY, +4, +6, +10, 12p+, +14, +17, +18, +20, +21 Not detected Positive 14.68
4 F 4 ALL B 46, XX Not detected Positive 2.68
5 F 4 ALL B ALL/53–55XX, +X, 1q+, +4, +6, +10, +11, +15, +17, +21 Not detected Positive 11.52
Table 2 Pathologic features and inhibition of cell growth by LEE011 in primary culture cells of pediatric AML
Gender Age Diagnosis AML typing Chromosome analysis Fusion gene CDK6 IC50 μM
1 F 9 AML M4 46, XX FLT3‑ITD Positive 2.54
2 F 3 AML M4 46, XX, inv(16)(p13q22) CBF/MYH11 Positive 8.46
3 M 4 AML M5b 46, XY, −2, +10, t(10;10)(p13;q23) MLL/AF10 Positive 1.94
4 M 12 AML M2a 45, X, −Y, t(8;21)(q22;q22) AML/ETO Positive 5.04
5 F 1 AML M4 46, XX, inv(16)(p13q22) 46, XY, inv(16)(p13q22) Positive 2.98
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MA, USA), PARP (Cat: 9542S, 1:1000, Cell Signal-
ing Technology, Inc. Danvers, MA, USA), CDK6 (Cat: 
13331S 1:1000, Cell Signaling Technology, Inc. Danvers, 
MA, USA), CDK4 (Cat: 12790S 1:1000, Cell Signaling 
Technology, Inc. Danvers, MA, USA), Cyclin D1 (Cat: 
2978S 1:1000, Cell Signaling Technology, Inc. Danvers, 
MA, USA), Cyclin D2 (Cat: 3741S 1:1000, Cell Signal-
ing Technology, Inc. Danvers, MA, USA), RB (Cat: 9313S 
1:1000, Cell Signaling Technology, Inc. Danvers, MA, 
USA), p-RB (Cat: 8516S 1:1000, Cell Signaling Technol-
ogy, Inc. Danvers, MA, USA), KIF20A (Cat: ab85644 
1:1000, Abcam Trading (Shanghai) Company Ltd. 
Pudong, Shanghai, China), PLK1 (Cat: 4535S 1:1000, Cell 
Signaling Technology, Inc. Danvers, MA, USA), MYBL2 
(Cat:BA3860 1:1000, BOSTER (Wuhan) Company Ltd. 
Wuhan, Chin), p16INK4a (Cat: ab189302 1:1000, Abcam 
Trading (Shanghai) Company Ltd. Pudong, Shanghai, 
China), p21 Waf1/Cip1 (Cat: 2946S 1:1000, Cell Signaling 
Technology, Inc. Danvers, MA, USA),GAPDH (1:5000, 
Sigma, St. Louis, MO, USA).
Real‑time PCR analysis certification of dyes‑regulated 
genes in LEE011‑treated HL‑60 cells
Quantitative real-time PCR was performed to determine 
the expression levels of dyes-regulated genes in 1  μM 
LEE011-treated HL-60 cells. Real-time PCR analysis was 
introduced before [26]. cDNA synthesis was performed 
on 4 μg of RNA in a 10 μl sample volume using Super-
Script II reverse transcriptase (Invitrogen Co., NY, USA) 
as recommended by the manufacturer. Reactions were run 
on Light cycler 480 using the universal thermal cycling 
parameters. The real time PCR primers used to quantify 
GAPDH expression were: F: 5′-AGAAGGCTGGGGCTC 
ATTTG-3′ and R: 5′-AGGGGCCATCCACAGTCTTC-3′;
CR1L were F: 5′-GTCCTCCTTCTCCGATCAATGC-3′ 
and R: 5′-CTTAGCACTTGTCCAGACTGAG-3′; TCP11L2 
were F: 5′-CTAAATGCTGACCCTCCTGAGT-3′ and R: 
5′- GCCACCGGGAGTGAGAAAA-3′; CR1 were F: 5′-AG 
AGGGACGAGCTTCGACC-3′ and R: 5′-TCAGGACGGC 
ATTCGTACTTT-3′; AMICA1 were F: 5′-GTTTCCCCGC 
CTGAGCTAAC-3′ and R: 5′-TTCTGGAAGCGCCCAAT 
AGG-3′; MCM10 were F: 5′-AAGCCTTCTCTGGTCTG 
CG-3′ and R: 5′-CTGTGGCGTAACCTTCTTCAA-3′; 
CDK1 were F: 5′-AAACTACAGGTCAAGTGGTAGCC-3′ 
and R: 5′-TCCTGCATAAGCACATCCTGA-3′; DLGAP5 
were F: 5′-AAGTGGGTCGTTATAGACCTGA-3′ and R: 
5′-TGCTCGAACATCACTCTCGTTAT-3′; KIF20A were 
F: 5′-TGCTGTCCGATGACGATGTC-3′ and R: 5′-AGGTT 
CTTGCGTACCACAGAC-3′; S100A8 were F: 5′-CATGC 
CGTCTACAGGGATGA-3′ and R: 5′- GACGTCTGCA 
CCCTTTTTCC-3′; IL8 were F: 5′-GAATGGGTTTGCTA 
GAATGTGATA-3′ and R: 5′-CAGACTAGGGTTGCCA 
GATTTAAC-3′; PLK1 were F: 5′- CTCAACACGCCT 
CATCCTC-3′ and R: 5′-GTGCTCGCTCATGTAATT 
GC-3′; MYBL2 were F: 5′-TGCCAGGGAGGACAGAC 
AAT-3′ and R: 5′-CTGTACCGATGGGCTCCTGTT-3′; 
PADI4 were F: 5′-AGTGGCTTGCTTTCTTCTCCTG 
TG-3′ and R: 5′-AGCAGAACTGAGTGTGCAGTGC 
TA-3′. Expression of genes was normalized to endogenous 
GAPDH expression.
Cluster analysis of the data was performed with gene 
cluster from the real-time PCR arrays. For gene expres-
sion quantification, we used the comparative Ct method. 
First, gene expression levels for each sample were nor-
malized to the expression level of the housekeeping gene 
encoding glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) within a given sample (−ΔCt). The relative 
expression of each gene was calculated using the equa-
tion: 106*Log2 (−ΔCt). Gene expression between the 
DMSO and the LEE011 samples were analyzed using 
Multi Experiment View (MEV) cluster software.
Interfering expression of LEE011 target genes in leukemia 
cells with RNAi lentivirus
RNAi lentivirus was purchased from Shanghai Genechem 
Co., Ltd. (http://www.genechem.com.cn). RNAi prod-
ucts target-specific lentivirus designed to knockdown 
MYBL2 expression; sequences are 1# 5-CAGATCA-
GAAGTACTCCAT-3; for KIF20A, sequences are 1# 5- 
CAGAAGAATATAAGGCTGT-3; for PLK1, sequences 
are 1# 5-CAACCAAAGUCGAAUAUGA-3. The control 
sequence is 5-TTCTCCGAACGTGTCACGT-3. Lentivi-
rus infection was according to the manufacture of Shang-
hai Genechem Co., Ltd. at a final concentration of 100–200 
MOI (multiplicity of infection). Interference efficiency was 
measured by western blot at 3 days after transfection. The 
rest cells were harvested for further analysis.
Statistical analysis
Each experimental condition was performed for three 
times, and these replicates were presented in results and 
figures. All values are presented as mean ± SEM. Student’s 
paired t test was applied to reveal statistical significances. 
P values less than 0.05 were considered significant. Statisti-
cal analyses were performed using SPSS Software for Win-
dows (version 11.5; SPSS, Inc., Chicago, IL, USA).
Results
Inhibitory effect of LEE011 on acute leukemia cell growth
Western blot analysis showed that expression of CDK6 
was very high in seven of nine of the leukemia cell lines 
investigated, the exceptions being THP-1 and U937 
cells (Fig. 1a). CDK4, Cyclin D1 and Cyclin D2 were also 
examined with Western blot analysis. Our results indi-
cated that there is positive correlation between IC50 
and the expression of Cyclin D1. LEE011 is novel CDK4/
Page 5 of 17Tao et al. Cancer Cell Int  (2017) 17:35 
CDK6 inhibitor with very high specificity (Fig.  1b). 
LEE011 treatment resulted in inhibition of proliferation 
of leukemia cells in a dose-dependent manner (Fig.  1c). 
Cell morphology and cell number of HL-60 and MV4-11 
cells were analyzed; there were changes in cell number 
following LEE011 treatment at concentrations of 2 and 
5 µM but no alteration in cellular morphology (Fig. 1d). 
To  better understand  the efficacy of LEE011, IC50 val-
ues of LEE011 in primary acute lymphoblastic leukemia 
(ALL) and AML cells were analyzed (Tables  1, 2). Our 
results showed that in primary ALL cells, the IC50 of 
LEE011 was 1.73–14.68  µM and in primary AML cells 
the IC50 of LEE011 was 1.94–8.46  µM (Fig.  1e). These 
results confirm that LEE011 is an effective anti-leukemia 
inhibitor.
LEE011 can induce apoptosis in leukemia cells
We investigated apoptosis in leukemia cells following 
LEE011 treatment. Cells treated with LEE011 at 2 and 
5  µM for 48  h showed more apoptotic features when 
compared to controls in seven leukemia cell lines, the 
exception being THP-1 (Fig.  2). To further demonstrate 
whether LEE011 causes apoptosis in leukemia cells, we 
assessed the expression and cleavage of the apoptosis 
markers PARP, caspase-3 and caspase-9 by western blot. 
After 48-h treatment with 2 and 5 µM LEE011, an increase 
in cleaved PARP was observed in the LEE011 treatment 
group for both MV4-11 and HL-60 cells (Fig. 3c).
Hoechst 33,342 staining analysis showed that DNA 
fragmentation and an increase in cells with nuclear 
abnormalities were observed after 24-h LEE011 treat-
ment (Fig.  3a). Abnormal nuclear structure in cells 
increased significantly compared with DMSO treated 
control cells in both HL-60 and MV4-11 cell lines 
(Fig.  3b). The proportion of MV4-11 cells with abnor-
mal nuclear structure in the 5-µM treatment group 
was 28.93 ± 6.50 vs. 5.60 ± 2.29% for the DMSO group 
(P = 0.0016); in HL-60 cells, 25.60 ± 3.30% of cells had 
abnormal nuclear structure in the 5-µM treatment 
group, compared with 3.27 ± 1.84% in the DMSO group 
(P = 0.0013).
LEE011 induced G1 arrest and cellular senescence 
in leukemia cells
Cell cycle analysis was undertaken on cells treated with 
LEE011 at 2 and 5  µM for 48  h (Additional files 1, 2). 
LEE011 significantly induced cell cycle G1 arrest in acute 
leukemia cells except THP-1 cells (Fig.  4). Cell senes-
cence β-galactosidase staining analysis was used in three 
leukemia cell lines: MV4-11, HL-60 and NB4. These 
cells were treated with LEE011 at 2  µM for 24–72  h 
before analysis (Fig. 5). More cells were β-galactosidase 
staining-positive following LEE011 treatment compared 
to DMSO controls. In MV4-11 and HL-60 cells, cell 
senescence marker p16INK4a was upregulated signifi-
cantly when the cells were treated with LEE011 for 48 h 
(Fig. 3c). 
Microarray analysis of genes and LncRNA expression 
profiles in LEE011‑treated HL‑60 cells
The Arraystar Human LncRNA 8 × 60 k v3.01 microar-
ray was used to identify mRNA and lncRNA expression 
profiles in 1  µM LEE011-treated HL-60 cells compared 
with a non-treated control group. Microarray analysis 
and original data have been submitted to the GEO data-
base with accession number GSE81060. In the lncRNA 
and mRNA expression profiling data we identified 2083 
differentially expressed mRNAs in LEE011-treated 
HL-60 cells compared with the controls. Compared with 
the control group, 116 mRNAs were upregulated and 
155 mRNAs were downregulated at the level of >fivefold 
change in LEE011 treated HL-60 cells. Clustering analy-
sis of these mRNA expression patterns is presented in 
Fig.  6a, c and Additional files 3, 4. In lncRNA analysis, 
3224 lncRNAs were differentially expressed in LEE011-
treated HL-60 cells from a total of 33,327 lncRNAs. Hier-
archical clustering analysis of the differently expressed 
lncRNAs (fold change ≥5) is presented in Fig. 6b, d and 
Additional files 5, 6.
In our system hundreds of brain-derived neuro-
trophic factor (BDNF) related lncRNAs were upregu-
lated, including BDNF-AS (NR_033313, NR_002832, 
ENST00000530313, ENST00000532965) and BDNF-
AS1 (uc009yis.3). BDNF plays an important role in 
the aging process [27]. BDNF helps to protect neurons 
from damage caused by infection or injury. A study 
performed in rats showed that TrkB (a BDNF recep-
tor) is markedly decreased during the aging process 
[28]. DLGAP1 related lncRNAs such as uc002kmi.3, 
ENST00000573177, uc010wzb.2, uc002kmj.1, 
NR_024101, ENST00000575606, ENST00000573355 and 
ENST00000576606 were also upregulated in our system. 
DLGAP1 plays a fundamental role in centrosome posi-
tioning and cell polarity. Centrosome positioning is cru-
cial for cellular senescence [28].
Gene ontology and KEGG pathway analysis of mRNA 
expression profiles in LEE011‑treated HL‑60 cells
Gene ontology pathway enrichment analysis was per-
formed for the differentially expressed genes identified 
through microarray analysis. Fisher’s exact test was used 
to determine whether the differential expression was 
greater than that expected by chance. For the upregulated 
transcripts (Fig.  7a), the most enriched gene ontologies 
(GOs) included immune response (P  =  1.69936E−13), 
immune system process (P  =  1.71894E−13), defense 
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Fig. 1 Inhibitory effect of LEE011 on leukemia cell growth. a Western blot analysis showing the expression of CDK6, CDK4, Cyclin D1 and Cyclin 
D2 in nine leukemia cell lines. Our results indicated that there is positive correlation between IC50 and the expression of Cyclin D1. b Molecular 
structure of LEE011. c Proliferation and IC50 analysis of LEE011 in six leukemia cells. IC50s: U937 3.7 µM, HL60 0.5 µM, NB4 2.6 µM, MV4‑11 2.1 µM, 
K562 13.1 µM and CCRF 8.6 µM. d Micrographs of HL‑60 and MV4‑11 cells treated with LEE011 (2 and 5 µM) or DMSO. e The IC50 of LEE011 in pri‑
mary ALL and AML cells was also analyzed. In primary ALL cells, the IC50 of LEE011 was 1.73–14.68 µM; in primary AML cells the IC50 of LEE011 was 
1.94–8.46 µM. All experiments were performed in quadruplicate. *P < 0.05, **P < 0.01
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Fig. 2 Analysis of apoptosis in leukemia cells induced by LEE011. Annexin V staining of cells following 48‑h treatment with LEE011 at 2 or 5 µM 
compared with DMSO controls. Following 5‑µM LEE011 treatment, the K562 apoptotic cell percentage was 5.9 ± 0.75 vs. 1.2 ± 0.66% for the DMSO 
group, P = 0.001; in MV4‑11 cells, the apoptotic cell percentage was 24.2 ± 3.06 vs. 0.53 ± 0.40% for the DMSO group, P = 0.005; in U937 cells, 
the apoptotic cell percentage was 9.9 ± 2.81 vs. 0.57 ± 0.42% for the DMSO group, P = 0.027; in HL‑60 cells, the apoptotic cell percentage was 
28.23 ± 6.01 vs. 0.9 ± 0.8% for the DMSO group, P = 0.015; in THP‑1 cells, the apoptotic cell percentage was 1.76 ± 0.4 vs. 1.56 ± 0.45% for the 
DMSO group, P = 0.59; in CCRF cells, the apoptotic cell percentage was 13.77 ± 3.16 vs. 1.2 ± 0.36% for the DMSO group, P = 0.019; in NB4 cells, 
the apoptotic cell percentage was 12.1 ± 1.35 vs. 0.86 ± 0.25% for the DMSO group, P = 0.004; and in SHI‑1 cells the apoptotic cell percentage was 
12.6 ± 2.81 vs. 1.87 ± 0.75% for the DMSO group, P = 0.017. These analyses were repeated three times. *P < 0.05; **P < 0.01
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Fig. 3 Analysis of apoptosis and cellular senescence markers induced by LEE011 in leukemia cells. a Hoechst 33,342 staining analysis showing 
cells treated with LEE011 at 2 and 5 µM, demonstrates an increase in cells with DNA fragmentation and abnormal nuclear structure following 
48‑h LEE011 treatment. b The number of cells with abnormal nuclear structure was calculated in each group. For MV4‑11 cells, the proportion 
with abnormal nuclear structure in the 5‑µM treatment group was 28.93 ± 6.50% vs. DMSO group 5.60 ± 2.29%, P = 0.0016; for HL‑60 cells, the 
respective values were 25.60 ± 3.30 vs. 3.27 ± 1.84%, P = 0.0013. **P < 0.01. c Western blotting of molecular markers of apoptosis, including PARP, 
caspase‑3 and caspase‑9, and molecular markers of cellular senescence, p16INK4a and p21Waf1/Cip1. Upregulation of p16INK4a was observed in the 
LEE011‑treatment groups for both MV4‑11 and HL‑60 cells
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Fig. 4 Cell cycle analysis of leukemia cells treated with LEE011. Cell cycle analysis showing cells treated with LEE011 at 2 or 5 µM for 48 h, in 
eight leukemia cell lines. LEE011 significantly induced cell cycle G1 arrest. The G1 phase cell percentage following 5‑µM LEE011 treatment of 
K562 cells was 81.23 ± 3.84% vs. DMSO group 32.46 ± 2.21%, P < 0.01. The G1 phase cell percentage in CCRF cells treated with 5 µM LEE011 was 
89.83 ± 2.67% vs. DMSO group 45.80 ± 3.24%, P < 0.01. The G1 phase cell percentage in NB4 cells treated with 5 µM LEE011 was 94.79 ± 4.93% vs. 
DMSO group 45.59 ± 3.12%, P < 0.01. The G1 phase cell percentage in HL‑60 cells treated with 5 µM LEE011 was 95.50 ± 2.97% vs. DMSO group 
47.40 ± 3.00%, P < 0.01. The G1 phase cell percentage in MV4‑11 cells treated with 5 µM LEE011 was 83.82 ± 2.81% vs. DMSO group 44.66 ± 1.90%, 
P < 0.01. The G1 phase cell percentage in SHI‑1 cells treated with 5 µM LEE011 was 87.39 ± 2.80% vs. DMSO group 45.25 ± 4.61%, P < 0.01. The 
G1 phase cell percentage in THP‑1 cells treated with 5 µM LEE011 was 50.51 ± 8.17% vs. DMSO group 45.64 ± 6.46%, P = 0.466. The G1 phase cell 
percentage in U937 cells treated with 5 µM LEE011 was 89.99 ± 3.54% vs. DMSO group 54.26 ± 2.92%, P < 0.01. **P < 0.01
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Fig. 5 β‑Galactosidase staining analysis of leukemia cells treated with LEE011. Leukemia cells were treated with 2.0 µM LEE011 for 24–72 h before 
analysis; more cells stained β‑galactosidase positive in the LEE011‑treatment group compared with the DMSO control group. For MV4‑11 cells, 
3‑days‑treated LEE011 group positive cells were 54.77 ± 6.68% vs. DMSO group 7.17 ± 0.95%, P = 0.006; in HL60 cells, 3‑days‑treated LEE011 
group positive cells were 75.43 ± 12.67% vs. DMSO group 6.20 ± 1.00%, P = 0.0011; in NB4 cells, 3‑days‑treated LEE011 group positive cells were 
82.10 ± 7.55% vs. DMSO group 7.17 ± 1.12%, P = 0.003. **P < 0.01
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response (P  =  3.32706E−13) and response to stimulus 
(P  =  2.09266E−12). For the downregulated transcripts 
(Fig.  7b), the most enriched GOs included mitotic cell 
cycle (P = 1.03536E−96), cell cycle (P = 1.62994E−88), cell 
cycle process (P  =  7.37652E−84) and mitotic cell cycle 
process (P  =  1.36566E−81). We further investigated the 
pathways in which these differentially expressed genes 
are involved through KEGG database analysis. The five 
most enriched pathways from KEGG analysis are shown 
in Fig.  7c, d. Notably, the downregulated pathways 
included cell cycle and DNA replication pathways.
LEE011 induced cellular senescence in leukemia cells 
partially through downregulation of the transcriptional 
expression of MYBL2
To identify the cellular senescence molecules impli-
cated in the mechanism of LEE011, the expressions of 
certain dysregulated genes identified in the gene array 
were confirmed using real-time PCR and western blot 
analyses. Cluster analysis of the real-time PCR results 
showed dysregulated genes in HL-60 cells treated with 
1 µM LEE011 for 24–72 h (Fig. 7e). Western blot anal-
ysis showed the downregulation of KIF20A, PLK1 and 
MYBL2 (Fig.  8a). These results are consistent with the 
real-time PCR analysis. Our western blot analysis also 
showed that LEE011 treatment could decrease the phos-
phorylation of RB and expression of CDK4/6 (Fig. 8a).
The molecular function of MYBL2, PLK1 and 
KIF20A was also analyzed in HL-60 cells. RNA inter-
ference of MYBL2 significantly downregulated the 
expression of MYBL2. Cell proliferation was also 
inhibited when the expression of MYBL2 was down-
regulated by RNA interference (Fig.  8b). Figure  8c, 
d show that downregulation of PLK1 and KIF20A 
resulted in inhibition of proliferation and induction of 
apoptosis in HL-60 cells.
Cell senescence β-galactosidase staining analysis showed 
that in the Si-MYBL2 group, the number of positive cells 
was increased compared with the Si-Nc control group 
(Fig. 9a). Cell cycle analysis showed that G1 phase cells in 
the Si-MYBL2 group increased significantly (Fig. 9b). DNA 
staining with Hochest 33,342 showed that nucleus became 
larger and irregular in the Si-MYBL2 group cells (Fig. 9c). 
These results imply that LEE011 induced senescence in 
AML cells, partially through down regulation of the tran-
scriptional expression of MYBL2. MYBL2 may be a new 
target of LEE011, but molecular function analysis of other 
target genes of LEE011 is still required.
Discussion
Currently, three selective CDK4/6 inhibitors, palboci-
clib (PD-0332991), ribociclib (LEE011) and abemaciclib 
(LY2835219), have been clinically approved or are in late-
stage clinical trials [29]. LEE011 (ribociclib) is an orally-
applied, effective small molecule that inhibits CDK4/6 at 
nanomolar concentrations. Antitumor activity of LEE011 
has been demonstrated in several cancer models. Sixteen 
active clinical trials are currently underway with LEE011 
as a single agent or in use in combination with other drugs 
[30, 31]. Most trials with LEE011 are for solid tumors 
including melanoma, breast cancer and neuroblastoma, 
and there have been no clinical trials of LEE011 in leukemia 
or other cancers of the hemopoietic system. In this study, 
we showed for the first time that LEE011 treatment results 
in inhibition of cell proliferation and induction of G1 arrest 
and senescence in leukemia cells. The lncRNA microar-
ray was used to determine mRNA and lncRNA expression 
profiles in LEE011-treated HL-60 cells and demonstrated 
(See figure on next page.) 
Fig. 7 Gene ontology and KEGG pathway analysis of mRNA expression profiles in LEE011‑treated HL‑60 cells. a The most enriched GO terms for 
upregulated transcripts. b The most enriched GO terms for downregulated transcripts. c The top five enriched pathways for upregulated transcripts 
from KEGG pathway analysis. d The top five enriched pathways for downregulated transcripts from KEGG pathway analysis. The most enriched 
pathway was cell cycle, with a P value of 2.54981E−23. The cell cycle pathway included BUB1, BUB1B, BUB3, CCNA1, CCNA2, CCNB1, CCNB2, CCNE2 
and CDC25A, amongst others. e Cluster analysis of several genes whose expression was detected by real‑time PCR in HL‑60 cells treated with 1uM 
LEE011 for 24, 48 and 72 h. Gene expression levels for each sample were normalized to the expression level of GAPDH within a given sample (−∆Ct). 
The relative expression of each gene was calculated using the equation: 106 × log2 (−∆Ct). Gene expression differences between the DMSO‑
treated and the LEE011‑treated samples were analyzed using Multi Experiment View (MEV) cluster software
(See figure on previous page) 
Fig. 6 Microarray analysis of gene and LncRNA expression profiles in LEE011‑treated HL‑60 cells. The Arraystar Human LncRNA 8 × 60 k v3.0 1 
microarray was used to identify mRNA and lncRNA expression profiles in LEE011‑treated HL‑60 cells compared with controls. a Hierarchical cluster‑
ing analysis of the 116 and 155 significantly up‑ and downregulated mRNAs (≥fivefold) in LEE011‑treated HL‑60 cells. b Hierarchical clustering 
analysis of the differently expressed lncRNAs with a fold‑change ≥5 in LEE011‑treated HL‑60 cells. c Scatter-plot showing mRNA expression variation 
between the control group and LEE011 treated HL‑60 cells. The green lines are fold‑change lines (the default fold‑change value given is 2.0). d 
Scatter-plot showing lncRNA expression variation between the control group and LEE011‑treated HL‑60 cells
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Fig. 8 Molecular mechanism analysis of cellular senescence induced by LEE011 in leukemia cells. a Dysregulated genes, KIF20A and MYBL2, identi‑
fied from gene arrays were confirmed by western blot analysis. b RNA interference of MYBL2 significantly down regulates the expression of MYBL2 
in HL‑60 cells. Proliferation analysis of Si‑MYBL2 at 4 days showed an OD450 value of 0.79 ± 0.29 vs. Si‑Nc 2.43 ± 0.43, P < 0.01. Apoptosis analysis 
showed Si‑MYBL2 was 9.06 ± 1.62% vs. Si‑Nc 4.36 ± 0.31%, P = 0.034. c RNA interference significantly downregulates the expression of PLK1 in 
HL‑60 cells. Proliferation analysis of Si‑MYBL2 at 4 days showed an OD450 value of 0.67 ± 0.29 vs. Si‑Nc 2.43 ± 0.43, P < 0.01. Apoptosis analysis 
showed Si‑MYBL2 was 25.26 ± 4.91% vs. Si‑Nc 3.67 ± 0.89%, P < 0.01. d RNA interference significantly downregulates the expression of KIF20A 
in HL‑60 cells. Proliferation analysis of Si‑MYBL2 at 4 days showed an OD450 value of 1.13 ± 0.39 vs. Si‑Nc 2.43 ± 0.43, P < 0.05. Apoptosis analysis 
showed Si‑MYBL2 was 11.9 ± 2.35% vs. Si‑Nc 4.13 ± 0.81%, P = 0.02. *P < 0.05; **P < 0.01
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Fig. 9 LEE011 induced cellular senescence in leukemia cells partially through downregulation of the transcriptional expression of MYBL2. a Cell 
senescence β‑galactosidase staining analysis showed that in the Si‑MYBL2 group, positively stained cells increased compared with the Si‑Nc control 
group: Si‑MYBL2 group 40.63 ± 4.48% vs. Si‑Nc group 6.57 ± 1.42%, P = 0.003. b Cell cycle analysis showed that G1 phase cells in the Si‑MYBL2 
group increased significantly: Si‑MYBL2 group 64.67 ± 1.98% vs. Si‑Nc group 45.73 ± 3.72%, P = 0.004. c DNA staining with Hochest 33,342 showed 
that nucleus became larger and irregular in the Si‑MYBL2 group cells. **P < 0.01
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that LEE011 induced cellular senescence partially through 
downregulation of the expression of MYBL2.
MYBL2 is emerging as an important gene in cellu-
lar senescence. When cells are senescing, MYBL2 has 
been shown to consistently be the most downregulated 
gene [32]. As reported previously, ectopic expression of 
MYBL2 in HMF3A cells can bypass cell senescence [33]. 
In rodent cells, premature senescence caused by the Ras 
oncogene can be rescued by MYBL2 expression. Moreo-
ver, downregulation of MYBL2 with siRNA silencing leads 
to increased senescence in primary human foreskin fibro-
blasts and HeLa cervical cancer cells [33]. These results 
strongly imply an important role for MYBL2 in senes-
cence. However, it remains to be determined what regu-
lates the expression of MYBL2 and whether MYBL2 could 
be a novel anti-tumor target [34]. In this study, MYBL2 was 
downregulated in HL-60 cells treated with LEE011 and 
cell senescence β-galactosidase staining analysis showed 
that in Si-MYBL2 cells, positive staining was increased 
when compared with the Si-Nc control group. Cell cycle 
analysis showed that G1 phase cells increased significantly 
and nucleus became larger and irregular in the Si-MYBL2 
group cells. These results imply that LEE011 induces 
senescence in AML cells partially through downregulation 
of the transcriptional expression of MYBL2. Therefore, our 
study may provide new clues into the mechanism of senes-
cence induced by LEE011 in AML cells.
Conclusions
In this study, we have shown that LEE011 treatment 
resulted in inhibition of cell proliferation and induction 
of G1 arrest and cellular senescence in leukemia cells. 
The lncRNA microarray was used to identify mRNA and 
lncRNA expression profiles in LEE011 treated HL-60 
cells and we demonstrated that LEE011 induces cellu-
lar senescence partially through downregulation of the 
expression of MYBL2. These results may provide new 
insights into the molecular mechanism of the anticancer 
effects of LEE011 and its potential as a candidate drug for 
leukemia; however, further research will be required to 
determine the underlying details.
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